{"id":"synflorixtm","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":null,"_fixedAt":"2026-03-30T12:15:00.169912","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide antigens from 13 serotypes of pneumococcus conjugated to a protein carrier, which enhances immunogenicity and promotes both antibody and T-cell mediated immunity. This elicits protective immune responses that prevent invasive pneumococcal disease and pneumococcal pneumonia across the covered serotypes.","oneSentence":"Synflorix is a pneumococcal conjugate vaccine that stimulates immune responses against multiple serotypes of Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:45.049Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in infants and children"},{"name":"Prevention of pneumococcal pneumonia in pediatric populations"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT00814710","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-07","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":360},{"nctId":"NCT01340898","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-27","conditions":"Meningococcal Infection","enrollment":753},{"nctId":"NCT00652951","phase":"PHASE3","title":"Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-01","conditions":"Infections, Streptococcal","enrollment":780},{"nctId":"NCT01235949","phase":"PHASE4","title":"Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-12","conditions":"Infections, Streptococcal","enrollment":850}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2023 May 5","pmid":"37045679","title":"Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix(TM) and Prevenar13(TM))) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian children.","journal":"Vaccine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SynflorixTM","genericName":"SynflorixTM","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Synflorix is a pneumococcal conjugate vaccine that stimulates immune responses against multiple serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia in pediatric populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}